 |
Combining therapies can improve survival for early-stage breast cancer patients
April 04, 2007Patients with early-stage breast cancer who are treated with both chemotherapy and tamoxifen have a higher survival rate than patients who receive only tamoxifen. But a combination of tamoxifen and ovarian suppression—treatment to stop the ovaries from functioning—did not show any additional benefits, according to two randomized clinical trials published in the April 4 Journal of the National Cancer Institute.
Survival rates improve for patients with early-stage breast cancer who receive a single method of treatment—either tamoxifen, ovarian suppression, or chemotherapy. Two international studies by the Adjuvant Breast Cancer Trials Collaborative Group were designed to test whether combining these treatments would provide additional benefits.
Judith Bliss of The Institute of Cancer Research in Sutton, England, and colleagues conducted two randomized controlled phase III clinical trials of 3,854 women with early-stage breast cancer, all of whom were treated with tamoxifen for five years. In the first trial, nearly half of the 2,144 premenopausal women were randomly assigned to receive ovarian suppression, and the other half did not. Some also received chemotherapy. In the second trial, 1,991 patients were randomly assigned to receive chemotherapy, and the other half were not. Some premenopausal women also had ovarian suppression.
The researchers found that chemotherapy treatment resulted in a modest yet sustained improvement in both relapse-free and overall survival. These improvements were especially strong in women younger than 50 years and in premenopausal women who did not receive ovarian suppression.
They also found that neither relapse-free survival nor overall survival was affected by the addition of ovarian suppression. However, the results indicate a possible benefit of ovarian suppression when given along side tamoxifen for a small group of women younger than 40 years who have ER-positive tumors (tumors that need estrogen to grow), especially when they are not receiving chemotherapy. The researchers called for further research into this group of breast cancer patients.
"Relapse-free survival benefits emerged early and were maintained, whereas overall survival benefits did not emerge for at least 5 years, reinforcing the need for long-term follow-up in chemotherapy trials," the authors write. The trials add "to the limited data available on the effects of combining long-term tamoxifen, chemotherapy, and ovarian ablation of suppression."
In an accompanying editorial, Kathleen Pritchard, M.D., of Toronto Sunnybrook Regional Cancer Centre, describes how the trial could have found more interesting results if there had been more data on patients' ER status. "Most of all, however, these studies stress the importance of establishing processes to ensure the availability of archived tumor specimens for all randomized adjuvant trials. The era in which such large important trials should be carried out without the archived correlational tumor samples is over."
Journal of the National Cancer Institute
Related Tamoxifen Current Events and Tamoxifen News Articles
Genetic and clinical factors best to predict late recurrence in estrogen receptor POS breast cancer
A new analysis has provided a comprehensive comparison of scores designed to predict which women with oestrogen-receptor positive breast cancer are at high risk of recurrence beyond five years after diagnosis, and may benefit from prolonged endocrine treatment.
Coffee may help prevent breast cancer returning, study finds
Drinking coffee could decrease the risk of breast cancer recurring in patients taking the widely used drug Tamoxifen, a study at Lund University in Sweden has found.
Researchers Identify New Pathway, Enhancing Tamoxifen to Tame Aggressive Breast Cancer
Tamoxifen is a time-honored breast cancer drug used to treat millions of women with early-stage and less-aggressive disease, and now a University of Rochester Medical Center team has shown how to exploit tamoxifen's secondary activities so that it might work on more aggressive breast cancer.
25% don't complete recommended breast cancer treatment
One-quarter of women who should take hormone-blocking therapies as part of their breast cancer treatment either do not start or do not complete the five-year course, according to a new study led by University of Michigan Comprehensive Cancer Center researchers.
Omega-3 fatty acids more effective at inhibiting growth of triple-negative breast cancer
Researchers from Fox Chase Cancer Center have found that omega-3 fatty acids and their metabolite products slow or stop the proliferation, or growth in the number of cells, of triple-negative breast cancer cells more effectively than cells from luminal types of the disease.
Tamoxifen ameliorates symptoms of Duchenne muscular dystrophy
A new study has found that tamoxifen, a well-known breast cancer drug, can counteract some pathologic features in a mouse model of Duchenne muscular dystrophy (DMD).
HRT for postmenopausal symptoms can be recommended as an alternative to hormone replacement therapy
Herbal and complementary medicines could be recommended as an alternative to hormone replacement therapy (HRT) for treating postmenopausal symptoms says a new review published today in The Obstetrician and Gynaecologist (TOG).
Delaying childbirth may reduce the risk of an aggressive form of breast cancer in younger women, study suggests
Younger women who wait at least 15 years after their first menstrual period to give birth to their first child may reduce their risk of an aggressive form of breast cancer by up to 60 percent, according to a Fred Hutchinson Cancer Research Center study.
Tamoxifen trial should prompt breast cancer patients to reconsider treatment options
A groundbreaking clinical trial involving the breast cancer drug tamoxifen should prompt certain breast cancer patients to reconsider their treatment options, according to Loyola University Medical Center breast cancer specialist Dr. Kathy Albain.
New Clues for Overcoming Tamoxifen-Resistant Breast Cancer
A University of Cincinnati (UC) cancer biology team reports breakthrough findings about specific cellular mechanisms that may help overcome endocrine (hormone) therapy-resistance in patients with estrogen-positive breast cancers, combating a widespread problem in effective medical management of the disease.
More Tamoxifen Current Events and Tamoxifen News Articles
 |
Tamoxifen and Breast Cancer (Yale Fastback Series) by Dr. Michael W. DeGregorio (Author), Valerie J. Wiebe (Author) This authoritative and timely book presents a balanced and accessible discussion of the diagnosis of breast cancer and the risks, benefits, and limitations of treatment alternatives, particularly tamoxifen. For this revised edition, the authors have added new information regarding the latest developments in the use of tamoxifen, especially the results of the Breast Cancer Prevention Trial. Other current issues discussed are raloxifene in chemoprevention, the use of hormone replacement therapy in breast cancer, new biologic agents, and other prevention strategies. |
|
Is Tamoxifen Safe and Effective?(for breast cancer treatment and prevention): An article from: Women's Health Letter by Nan Kathryn Fuchs (Author) This digital document is an article from Women's Health Letter, published by Soundview Publications on April 1, 2001. The length of the article is 1284 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Is Tamoxifen Safe and Effective?(for breast cancer treatment and prevention) Author: Nan Kathryn Fuchs Publication: Women's Health Letter (Newsletter) Date: April 1, 2001 Publisher: Soundview Publications Volume: 7 Issue: 4 Page: 3 Article Type: Product/Service Evaluation Distributed by Thomson... | |
 |
Tamoxifen Concepts and Cancer: New Paradigms (Cancer Etiology, Diagnosis and Treatments: Pharmacology - Research, Safety Testing and Regulation) by Ramon Andrade De Mello (Editor) Tamoxifen was first approved in 1977 and up to now remains a noteworthy therapeutic weapon to treat mainly breast cancer. However, further considerations exist regarding the tamoxifen profile. This book discusses recent research and future perspectives in the tamoxifen field. The topics discussed include tamoxifen pharmacokinetics, pharmacodynamics, adverse effects, clinical indications, therapeutic drug monitoring, autophagy mechanisms, tamoxifen topical formulation and breast cancer risk prevention, the use of tamoxifen in an oestrogen-independent manner for various neoplasms (Hepatocellular carcinoma, renal cell carcinoma, high grade glioma), mechanisms of resistance, potential role of CYP2D6, tamoxifen and antidepressants interaction in a psychiatric view, obesity influence in... |
|
Tamoxifen - the good and the bad.: An article from: Medical Update by Benjamin Franklin Literary & Medical Society, Inc. (Publisher) This digital document is an article from Medical Update, published by Benjamin Franklin Literary & Medical Society, Inc. on May 1, 1992. The length of the article is 591 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Tamoxifen - the good and the bad. Publication: Medical Update (Newsletter) Date: May 1, 1992 Publisher: Benjamin Franklin Literary & Medical Society, Inc. Volume: v15 Issue: n11 Page: p3(2) Distributed by Thomson... | |
 |
Tamoxifen: Beyond the Antiestrogen by Birkhäuser Tamoxifen is a drug used as an antisteroidal substance. This work looks at the effects of the Tamoxifen beyond the scope of simple oestrogen antagonism. It examines the numerous "side effects" of the drug and looks at the complexity of its actions. |
 |
Tamoxifen for the Treatment and Prevention of Breast Cancer by V. Craig Jordan PhD. DSC. (Author) Dr. V. Craig Jordan's conversations with hundreds of women with breast cancer and his passion to help find a cure for the disease have compelled him to gather eminent cancer specialists to contribute to this book. Distinguished physicians, scientists, breast cancer advocates, and breast cancer survivors have assembled here to answer numerous questions about tamoxifen. Written for both the clinician and patient, this book is a premier source of information about the world's leading drug for the treatment and prevention of breast cancer. |
 |
Tamoxifen: Webster's Timeline History, 1973 - 2007 by Icon Group International (Author) Webster's bibliographic and event-based timelines are comprehensive in scope, covering virtually all topics, geographic locations and people. They do so from a linguistic point of view, and in the case of this book, the focus is on "Tamoxifen," including when used in literature (e.g. all authors that might have Tamoxifen in their name). As such, this book represents the largest compilation of timeline events associated with Tamoxifen when it is used in proper noun form. Webster's timelines cover bibliographic citations, patented inventions, as well as non-conventional and alternative meanings which capture ambiguities in usage. These furthermore cover all parts of speech (possessive, institutional usage, geographic usage) and contexts, including pop culture, the arts, social sciences... |
 |
The Breast Cancer Survivor's Fitness Plan: A Doctor-Approved Workout Plan For a Strong Body and Lifesaving Results (Harvard Medical School Guides) by Carolyn Kaelin (Author), Francesca Coltrera (Author), Josie Gardiner (Author), Joy Prouty (Author) The only breast cancer recovery program designed by a Harvard doctor and survivor and approved by the American Council on Exercise (ACE) Feel healthy again. Regain control of your life. Exciting new research reveals that regular exercise can reduce the chance of breast cancer recurrence and extend your life. Exercise can also help you recover energy, strength, and flexibility diminished by lifesaving breast cancer treatments. Dr. Carolyn Kaelin is a leading breast cancer surgeon who understands the important links among exercise, recovery, and the quality of life--and she is a breast cancer survivor, too. Designed with master trainers Josie Gardner and Joy Prouty, The Breast Cancer Survivor's Fitness Plan features effective, inspiring workouts tailored for each type of surgery and... |
 |
Long-Term Tamoxifen Treatment by V. Craig Jordan (Author) During the past twenty years tamoxifen has become the most widely prescribed and most successful drug used in the treatment of breast cancer. In this volume, editor V. Craig Jordan provides articles that trace the development, pharmacology, and clinical research surrounding this drug which, by the year 2000, could be used to treat as many as one million women annually.    Drawing from research conducted by specialists in the United States, the United Kingdom, and Italy, the series of articles describes the clinical testing of tamoxifen, highlighting the benefits. Studies show that tamoxifen lowers cholesterol and can potentially protect women against osteoporosis and fatal coronary heart disease. Equally important is a discussion of side effects and possible drug interactions... |
 |
Antiestrogens induce immunosuppression: Tamoxifen and Fulvestrant lead to TGFß-mediated immunosuppression in breast cancer by Christian Joffroy (Author) Antiestrogens (AE) like tamoxifen belong to the most commonly used drugs in the therapy of estrogen receptor positive breast cancer. Nevertheless, relapses frequently occur during treatment indicating development of drug resistance. Concerning the underlying mechanisms, the finding of AE induced TGFß in breast cancer cells appears to be relevant both with respect to TGFß?s cell autonomous function as a mediator of cancer progression and its function as an immune regulator. To investigate the potential role of tumor derived, AE induced TGFß as a suppressor of the host?s immune response, heterologous and autologous in vitro assays have been established in this work. Application of AE led to an impaired antitumor immune response, which could be restored by a neutralizing... |
| © 2013 BrightSurf.com |